Clinical Trial Update: Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC [Phase 2]

View source ↗

Summary

Ongoing phase 2 trial evaluating enfortumab vedotin in advanced or metastatic colorectal cancer and hepatocellular carcinoma; study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Hepatocellular Carcinoma

Drugs mentioned

• Enfortumab Vedotin (enfortumab vedotin)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Metastatic Colorectal Cancer, Hepatocellular Carcinoma | Phase 2 | Status: RECRUITING